\-\ Texto\\:\\ \ \(0\)\
\-\ na\\,\\ k\\,\\ cl\\,\\ co2\\,\\ glucose\\,\\ bun\\,\\ creatinine\\,\\ ca\\,\\ drawn\\ on\\ the\\ same\\ day\\ the\\ ct\\ scan\\ was\\ taken\\ were\\ all\\ normal\\.\ \(0\)\
\-\ pt\\ is\\ currently\\ not\\ receiving\\ treatment\\ but\\ is\\ being\\ worked\\ up\\ followed\\ with\\ serial\\ ct\\ scans\\ due\\ to\\ unexplained\\ weight\\ loss\\.\ \(0\)\
\-\ 1\\.\\ the\\ parenchyma\\ of\\ the\\ lung\\ demonstrates\\ bilateral\\ upper\\ lobe\\ predominant\\ fibrotic\\ changes\\ with\\ interlobular\\ septal\\ thickening\\.\\ 2\\.\\ \\ numerous\\ 1\\ cm\\ nodular\\ densities\\ with\\ in\\ the\\ periphery\\.\ \(0\)\
\-\ 3\\.\\ \\ as\\ well\\ as\\ dominant\\ fibrotic\\ masses\\ at\\ the\\ end\\ of\\ the\\ bronchovascular\\ bundle\\ on\\ the\\ right\\ side\\ seen\\ best\\ on\\ image\\ \\#16\\ measuring\\ 3\\.6\\ cm\\ x\\ 1\\.7\\ cm\\ and\\ on\\ the\\ left\\ upper\\ lobe\\ seen\\ best\\ on\\ image\\ \\#10\\ measuring\\ 2\\.4\\ cm\\ x\\ 1\\.8\\ cm\\ with\\ associated\\ traction\\ bronchiectasis\\,\\ as\\ well\\ as\\ some\\ sparse\\ areas\\ of\\ effected\\ regions\\ within\\ the\\ superior\\ segments\\ of\\ the\\ lower\\ lobes\\ bilaterally\\ as\\ well\\ as\\ the\\ right\\ middle\\ lobe\\,\\ which\\ appears\\ to\\ have\\ not\\ changed\\ significantly\\ in\\ comparison\\ with\\ the\\ prior\\ ct\\ scan\\ performed\\ on\\ 27\\ feb\\ 2002\\.\ \(0\)\
\-\ 4\\.\\ \\ no\\ evidence\\ of\\ pleural\\ effusion\\ or\\ pneumothorax\\.\ \(0\)\
\-\ 5\\.\\ \\ mediastinum\\ demonstrates\\ no\\ evidence\\ of\\ lymphadenopathy\\ pathologic\\ by\\ size\\ criteria\\.\\ \\ \ \(0\)\
\-\ 6\\.\\ \\ no\\ evidence\\ of\\ axillary\\ lymphadenopathy\\ pathologic\\ by\\ size\\ criteria\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ nodular\\ interstitial\\ pattern\\:\\ granulomatous\\ diseases\\ both\\ infectious\\ \\(tb\\,\\ fungal\\,\\ bacteria\\,\\ atypical\\ mycobacterium\\)\\ and\\ non\\-\\ infectious\\ \\(sarcoidosis\\,\\ vasculitis\\-granulomatosis\\ diseases\\,\\ histiocytosis\\)\\ hematogenous\\ spread\\ of\\ malignancy\\,\\ and\\,\\ pneumoconiosis\\.\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ 70\\ y\\/o\\ female\\ for\\ follow\\ up\\ ct\\ scan\\ to\\ monitor\\ for\\ any\\ pulmonary\\ changes\\ due\\ to\\ a\\ recent\\ 15lb\\ weight\\ loss\\,\\ otherwise\\ asymptomatic\\.\ \(0\)\
\-\ sarcoidosis\\ is\\ a\\ granulomatous\\ disorder\\ of\\ unknown\\ etiology\\ that\\ can\\ affect\\ multiple\\ systems\\;\\ the\\ presence\\ of\\ noncaseating\\ granulomas\\ in\\ the\\ involved\\ organs\\ is\\ what\\ characterizes\\ it\\ pathologically\\.\\ \\ sarcoidosis\\ is\\ estimated\\ to\\ have\\ a\\ prevalence\\ of\\ 10\\-20\\ per\\ 100\\,000\\ and\\ is\\ 3\\-4\\ times\\ more\\ common\\ in\\ african\\ americans\\ than\\ caucasians\\.\\ \\ the\\ most\\ common\\ target\\ of\\ sarcoidosis\\ is\\ the\\ lungs\\,\\ around\\ 90\\%\\ of\\ all\\ patients\\ with\\ sarcoidosis\\ have\\ lung\\ involvement\\,\\ resulting\\ in\\ the\\ main\\ symptoms\\ including\\ cough\\,\\ dyspnea\\,\\ chest\\ pain\\,\\ and\\ the\\ less\\ common\\ features\\ include\\ fatigue\\,\\ weakness\\,\\ malaise\\,\\ fever\\,\\ and\\ weight\\ loss\\.\\ \\ sarcoidosis\\,\\ when\\ in\\ its\\ extrapulmonary\\ form\\,\\ can\\ result\\ in\\ a\\ plethora\\ of\\ other\\ complaints\\ depending\\ on\\ the\\ organ\\ system\\ affected\\.\\ \\ but\\ approximately\\ 50\\%\\ of\\ those\\ with\\ sarcoidosis\\ are\\ asymptomatic\\ at\\ the\\ time\\ it\\ is\\ discovered\\.\\ \\ the\\ treatment\\ for\\ sarcoidosis\\ is\\ not\\ straightforward\\.\\ \\ it\\ is\\ typically\\ agreed\\ upon\\ that\\ treatment\\ should\\ begin\\ if\\ the\\ patient\\ is\\ symptomatic\\,\\ if\\ lung\\ function\\ is\\ deteriorating\\,\\ or\\ the\\ radiological\\ findings\\ associated\\ with\\ sarcoidosis\\ are\\ worsening\\.\\ \\ the\\ current\\ primary\\ treatment\\ is\\ with\\ daily\\ oral\\ corticosteroids\\.\\ \\ the\\ best\\ dose\\ is\\ not\\ known\\ so\\ a\\ dose\\ must\\ be\\ chosen\\ by\\ balancing\\ the\\ risk\\ of\\ adverse\\ effects\\ versus\\ the\\ benefits\\ of\\ therapy\\.\\ \\ treatment\\ typically\\ lasts\\ between\\ 6\\ to\\ 12\\ months\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.07408236787649207\ \(0\)\
\-\ fibrotic\\:\\ 0\\.023445175519632582\ \(0\)\
\-\ cm\\:\\ 0\\.021995740094212915\ \(0\)\
\-\ best\\:\\ 0\\.020701512085728447\ \(0\)\
\-\ criteria\\:\\ 0\\.01793621381026858\ \(0\)\
\-\ \\,\\:\\ 0\\.017666299861012993\ \(0\)\
\-\ weight\\:\\ 0\\.01763692390676122\ \(0\)\
\-\ dose\\:\\ 0\\.017165884844962818\ \(0\)\
\-\ vasculitis\\-granulomatosis\\:\\ 0\\.01692038085214299\ \(0\)\
\-\ 15lb\\:\\ 0\\.01692038085214299\ \(0\)\
\-\ plethora\\:\\ 0\\.01692038085214299\ \(0\)\
\-\ treatment\\:\\ 0\\.01659901112860736\ \(0\)\
\-\ diseases\\:\\ 0\\.016524602370248172\ \(0\)\
\-\ granulomatous\\:\\ 0\\.015831748720680824\ \(0\)\
\-\ effected\\:\\ 0\\.015589963998860945\ \(0\)\
\-\ characterizes\\:\\ 0\\.015589963998860945\ \(0\)\
\-\ caucasians\\:\\ 0\\.015589963998860945\ \(0\)\
\-\ extrapulmonary\\:\\ 0\\.015589963998860945\ \(0\)\
\-\ balancing\\:\\ 0\\.015589963998860945\ \(0\)\
\-\ is\\:\\ 0\\.015109541069839076\ \(0\)\
\-\ as\\:\\ 0\\.01488572943448132\ \(0\)\
\-\ deteriorating\\:\\ 0\\.014811720029363509\ \(0\)\
\-\ pathologic\\:\\ 0\\.014358328632371098\ \(0\)\
\-\ loss\\:\\ 0\\.014282903104424797\ \(0\)\
\-\ sparse\\:\\ 0\\.0142595471455789\ \(0\)\
\-\ noncaseating\\:\\ 0\\.0142595471455789\ \(0\)\
\-\ straightforward\\:\\ 0\\.0142595471455789\ \(0\)\
\-\ lung\\:\\ 0\\.014252355778725986\ \(0\)\
\-\ infectious\\:\\ 0\\.014103089702356384\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.013949078209882584\ \(0\)\
\-\ scan\\:\\ 0\\.013775075587905826\ \(0\)\
\-\ nodular\\:\\ 0\\.013759730545535169\ \(0\)\
\-\ bundle\\:\\ 0\\.013481303176081464\ \(0\)\
\-\ agreed\\:\\ 0\\.013481303176081464\ \(0\)\
\-\ lasts\\:\\ 0\\.013481303176081464\ \(0\)\
\-\ lobe\\:\\ 0\\.013239877243321693\ \(0\)\
\-\ non\\-\\:\\ 0\\.013185428550693252\ \(0\)\
\-\ measuring\\:\\ 0\\.01311844807082052\ \(0\)\
\-\ unexplained\\:\\ 0\\.012929130292296856\ \(0\)\
\-\ americans\\:\\ 0\\.012929130292296856\ \(0\)\
\-\ evidence\\:\\ 0\\.012900821017467626\ \(0\)\
\-\ common\\:\\ 0\\.012876778571725896\ \(0\)\
\-\ \\#\\:\\ 0\\.012866359381730856\ \(0\)\
\-\ 3\\.6\\:\\ 0\\.012703059206584027\ \(0\)\
\-\ mycobacterium\\:\\ 0\\.012500831729313728\ \(0\)\
\-\ 100\\,000\\:\\ 0\\.012500831729313728\ \(0\)\
\-\ bronchovascular\\:\\ 0\\.012317894723931147\ \(0\)\
\-\ 10\\-20\\:\\ 0\\.012317894723931147\ \(0\)\
\-\ chosen\\:\\ 0\\.01199725348657382\ \(0\)\
\-\ interlobular\\:\\ 0\\.011855011697411207\ \(0\)\
\-\ adverse\\:\\ 0\\.011855011697411207\ \(0\)\
\-\ typically\\:\\ 0\\.011579369556644806\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.011482351400979428\ \(0\)\
\-\ worked\\:\\ 0\\.011268866496737156\ \(0\)\
\-\ can\\:\\ 0\\.011160589361626122\ \(0\)\
\-\ well\\:\\ 0\\.011130984374099718\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.011088646441443712\ \(0\)\
\-\ cl\\:\\ 0\\.01107676772791377\ \(0\)\
\-\ it\\:\\ 0\\.01106054731976785\ \(0\)\
\-\ size\\:\\ 0\\.010997604112778394\ \(0\)\
\-\ feb\\:\\ 0\\.010902157788939248\ \(0\)\
\-\ pathologically\\:\\ 0\\.010902157788939248\ \(0\)\
\-\ begin\\:\\ 0\\.010902157788939248\ \(0\)\
\-\ x\\:\\ 0\\.010821751767168817\ \(0\)\
\-\ benefits\\:\\ 0\\.010820469469517374\ \(0\)\
\-\ have\\:\\ 0\\.010655113695000528\ \(0\)\
\-\ predominant\\:\\ 0\\.010594398383804547\ \(0\)\
\-\ hematogenous\\:\\ 0\\.010594398383804547\ \(0\)\
\-\ co2\\:\\ 0\\.010524594844129162\ \(0\)\
\-\ 1\\.8\\:\\ 0\\.010524594844129162\ \(0\)\
\-\ granulomas\\:\\ 0\\.010524594844129162\ \(0\)\
\-\ changed\\:\\ 0\\.010392170906534246\ \(0\)\
\-\ bacteria\\:\\ 0\\.010392170906534246\ \(0\)\
\-\ 1\\.7\\:\\ 0\\.010329234586336567\ \(0\)\
\-\ malaise\\:\\ 0\\.010268296585732766\ \(0\)\
\-\ image\\:\\ 0\\.010246407548167373\ \(0\)\
\-\ 2\\.4\\:\\ 0\\.010209233901151665\ \(0\)\
\-\ drawn\\:\\ 0\\.010096296281146035\ \(0\)\
\-\ prevalence\\:\\ 0\\.010096296281146035\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.009989636298123366\ \(0\)\
\-\ age\\:\\ 0\\.009984300673874496\ \(0\)\
\-\ target\\:\\ 0\\.00988859266379434\ \(0\)\
\-\ traction\\:\\ 0\\.009792603372864089\ \(0\)\
\-\ on\\:\\ 0\\.00972598289166602\ \(0\)\
\-\ 3\\-4\\:\\ 0\\.009613926937036811\ \(0\)\
\-\ organ\\:\\ 0\\.009613926937036811\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.009571740935657203\ \(0\)\
\-\ effects\\:\\ 0\\.009571740935657203\ \(0\)\
\-\ receiving\\:\\ 0\\.00949005261623533\ \(0\)\
\-\ estimated\\:\\ 0\\.00949005261623533\ \(0\)\
\-\ radiological\\:\\ 0\\.00949005261623533\ \(0\)\
\-\ not\\:\\ 0\\.009480373679400656\ \(0\)\
\-\ affect\\:\\ 0\\.009450476249243514\ \(0\)\
\-\ organs\\:\\ 0\\.00941169945976651\ \(0\)\
\-\ changes\\:\\ 0\\.00940133580128622\ \(0\)\
\-\ creatinine\\:\\ 0\\.009336419780009732\ \(0\)\
\-\ monitor\\:\\ 0\\.009336419780009732\ \(0\)\
\-\ all\\:\\ 0\\.009278017233901308\ \(0\)\
\-\ segments\\:\\ 0\\.00922876245438393\ \(0\)\
\-\ include\\:\\ 0\\.00920212471412778\ \(0\)\
\-\ ct\\:\\ 0\\.009176995419516644\ \(0\)\
\-\ periphery\\:\\ 0\\.009160205673957674\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.009126824210019346\ \(0\)\
\-\ densities\\:\\ 0\\.009094013397429518\ \(0\)\
\-\ bun\\:\\ 0\\.009061754053252203\ \(0\)\
\-\ 2002\\:\\ 0\\.00896810690513429\ \(0\)\
\-\ months\\:\\ 0\\.008959467541996419\ \(0\)\
\-\ k\\:\\ 0\\.008937879732450721\ \(0\)\
\-\ septal\\:\\ 0\\.008937879732450721\ \(0\)\
\-\ axillary\\:\\ 0\\.008908121217026603\ \(0\)\
\-\ if\\:\\ 0\\.008901126425261556\ \(0\)\
\-\ na\\:\\ 0\\.008849953559645936\ \(0\)\
\-\ up\\:\\ 0\\.008820910368730223\ \(0\)\
\-\ glucose\\:\\ 0\\.00876587942786399\ \(0\)\
\-\ fatigue\\:\\ 0\\.00876587942786399\ \(0\)\
\-\ due\\:\\ 0\\.008753463159127983\ \(0\)\
\-\ gestational\\:\\ 0\\.008738653640931253\ \(0\)\
\-\ systems\\:\\ 0\\.008711808646737894\ \(0\)\
\-\ what\\:\\ 0\\.008659219444841321\ \(0\)\
\-\ african\\:\\ 0\\.008558175810512296\ \(0\)\
\-\ comparison\\:\\ 0\\.008533724705373275\ \(0\)\
\-\ depending\\:\\ 0\\.008533724705373275\ \(0\)\
\-\ daily\\:\\ 0\\.008485737561025065\ \(0\)\
\-\ significantly\\:\\ 0\\.008393219131432211\ \(0\)\
\-\ dominant\\:\\ 0\\.008370769918834913\ \(0\)\
\-\ end\\:\\ 0\\.008326644164085012\ \(0\)\
\-\ by\\:\\ 0\\.008193114606016554\ \(0\)\
\-\ serial\\:\\ 0\\.008179734227189938\ \(0\)\
\-\ discovered\\:\\ 0\\.008081282606484465\ \(0\)\
\-\ interstitial\\:\\ 0\\.00802454786129916\ \(0\)\
\-\ 6\\.\\:\\ 0\\.007969442091851115\ \(0\)\
\-\ fungal\\:\\ 0\\.007951419557590387\ \(0\)\
\-\ times\\:\\ 0\\.007951419557590387\ \(0\)\
\-\ spread\\:\\ 0\\.007933564677240457\ \(0\)\
\-\ upper\\:\\ 0\\.007915856066674542\ \(0\)\
\-\ mediastinum\\:\\ 0\\.007898345601101885\ \(0\)\
\-\ tb\\:\\ 0\\.007898345601101885\ \(0\)\
\-\ 70\\:\\ 0\\.007880975475343886\ \(0\)\
\-\ versus\\:\\ 0\\.007796407356737301\ \(0\)\
\-\ dyspnea\\:\\ 0\\.007763596544147472\ \(0\)\
\-\ associated\\:\\ 0\\.007740739201181197\ \(0\)\
\-\ 90\\:\\ 0\\.007731337199970158\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.007699611092578199\ \(0\)\
\-\ current\\:\\ 0\\.007683942550084607\ \(0\)\
\-\ form\\:\\ 0\\.0076684008797724785\ \(0\)\
\-\ \\%\\:\\ 0\\.007651904158717879\ \(0\)\
\-\ ca\\:\\ 0\\.007637690051852246\ \(0\)\
\-\ scans\\:\\ 0\\.007637690051852246\ \(0\)\
\-\ main\\:\\ 0\\.007637690051852246\ \(0\)\
\-\ 27\\:\\ 0\\.007607462879168677\ \(0\)\
\-\ regions\\:\\ 0\\.007505266114257329\ \(0\)\
\-\ must\\:\\ 0\\.007477039343835649\ \(0\)\
\-\ those\\:\\ 0\\.007463080112877722\ \(0\)\
\-\ so\\:\\ 0\\.007463080112877722\ \(0\)\
\-\ the\\:\\ 0\\.007429903976394476\ \(0\)\
\-\ 16\\:\\ 0\\.0074218014080390205\ \(0\)\
\-\ disorder\\:\\ 0\\.007368108793754172\ \(0\)\
\-\ numerous\\:\\ 0\\.007354917086867873\ \(0\)\
\-\ lobes\\:\\ 0\\.007227758957230252\ \(0\)\
\-\ resulting\\:\\ 0\\.007203307852091231\ \(0\)\
\-\ per\\:\\ 0\\.007179164316185549\ \(0\)\
\-\ demonstrates\\:\\ 0\\.007165532443966165\ \(0\)\
\-\ complaints\\:\\ 0\\.007120101631604448\ \(0\)\
\-\ atypical\\:\\ 0\\.007108504099059414\ \(0\)\
\-\ affected\\:\\ 0\\.007096976221784536\ \(0\)\
\-\ 5\\.\\:\\ 0\\.007074126121004654\ \(0\)\
\-\ but\\:\\ 0\\.006996173900320681\ \(0\)\
\-\ parenchyma\\:\\ 0\\.006985352574650036\ \(0\)\
\-\ function\\:\\ 0\\.006953093230472721\ \(0\)\
\-\ etiology\\:\\ 0\\.0069424594869494675\ \(0\)\
\-\ features\\:\\ 0\\.006921367123080763\ \(0\)\
\-\ oral\\:\\ 0\\.006910907229093114\ \(0\)\
\-\ involved\\:\\ 0\\.006879865272767584\ \(0\)\
\-\ taken\\:\\ 0\\.006839241834779018\ \(0\)\
\-\ around\\:\\ 0\\.006829218909671241\ \(0\)\
\-\ same\\:\\ 0\\.006760486754783121\ \(0\)\
\-\ 12\\:\\ 0\\.006712856871635857\ \(0\)\
\-\ upon\\:\\ 0\\.006703471103316871\ \(0\)\
\-\ symptomatic\\:\\ 0\\.00651628296486413\ \(0\)\
\-\ currently\\:\\ 0\\.006499371967393584\ \(0\)\
\-\ seen\\:\\ 0\\.0064822557200295205\ \(0\)\
\-\ in\\:\\ 0\\.0064705908658772345\ \(0\)\
\-\ 4\\.\\:\\ 0\\.006457735067947788\ \(0\)\
\-\ system\\:\\ 0\\.006457735067947788\ \(0\)\
\-\ worsening\\:\\ 0\\.006457735067947788\ \(0\)\
\-\ unknown\\:\\ 0\\.006400920346688112\ \(0\)\
\-\ pleural\\:\\ 0\\.006369194239296154\ \(0\)\
\-\ malignancy\\:\\ 0\\.006337984026490434\ \(0\)\
\-\ result\\:\\ 0\\.0062921001093051085\ \(0\)\
\-\ cough\\:\\ 0\\.006284558308652729\ \(0\)\
\-\ pattern\\:\\ 0\\.006269563030846983\ \(0\)\
\-\ 50\\:\\ 0\\.0062399194177424275\ \(0\)\
\-\ effusion\\:\\ 0\\.006232579501353937\ \(0\)\
\-\ lungs\\:\\ 0\\.006210726675585942\ \(0\)\
\-\ its\\:\\ 0\\.006189119853081845\ \(0\)\
\-\ appears\\:\\ 0\\.006105045721299901\ \(0\)\
\-\ pt\\:\\ 0\\.006098202983940024\ \(0\)\
\-\ weakness\\:\\ 0\\.006091384554756976\ \(0\)\
\-\ involvement\\:\\ 0\\.006011398573181989\ \(0\)\
\-\ middle\\:\\ 0\\.005998385738277231\ \(0\)\
\-\ presence\\:\\ 0\\.005953523259994489\ \(0\)\
\-\ risk\\:\\ 0\\.005940895676313025\ \(0\)\
\-\ including\\:\\ 0\\.00592210871591732\ \(0\)\
\-\ otherwise\\:\\ 0\\.005891200064158051\ \(0\)\
\-\ or\\:\\ 0\\.005766925617833249\ \(0\)\
\-\ being\\:\\ 0\\.005715523947793778\ \(0\)\
\-\ side\\:\\ 0\\.0056822389669176025\ \(0\)\
\-\ that\\:\\ 0\\.005665952892740205\ \(0\)\
\-\ 3\\.\\:\\ 0\\.005612042633667423\ \(0\)\
\-\ thickening\\:\\ 0\\.005559740056992998\ \(0\)\
\-\ less\\:\\ 0\\.005554587340350638\ \(0\)\
\-\ fever\\:\\ 0\\.005549448419485539\ \(0\)\
\-\ masses\\:\\ 0\\.005544323220721856\ \(0\)\
\-\ 10\\:\\ 0\\.005529029229072765\ \(0\)\
\-\ areas\\:\\ 0\\.005518900520625847\ \(0\)\
\-\ recent\\:\\ 0\\.005513856139807672\ \(0\)\
\-\ followed\\:\\ 0\\.005498802056389197\ \(0\)\
\-\ bilaterally\\:\\ 0\\.005387150169911523\ \(0\)\
\-\ superior\\:\\ 0\\.005237511894537795\ \(0\)\
\-\ should\\:\\ 0\\.005228807182128215\ \(0\)\
\-\ 2\\.\\:\\ 0\\.005215823688676119\ \(0\)\
\-\ follow\\:\\ 0\\.005211515301240756\ \(0\)\
\-\ day\\:\\ 0\\.005207216563057446\ \(0\)\
\-\ between\\:\\ 0\\.0051986478622346325\ \(0\)\
\-\ known\\:\\ 0\\.005190117244652245\ \(0\)\
\-\ any\\:\\ 0\\.00516475054332494\ \(0\)\
\-\ 1\\.\\:\\ 0\\.005123203774083687\ \(0\)\
\-\ approximately\\:\\ 0\\.0050745063849435374\ \(0\)\
\-\ days\\:\\ 0\\.005027014004168863\ \(0\)\
\-\ some\\:\\ 0\\.004980668433525449\ \(0\)\
\-\ no\\:\\ 0\\.0049545728447435815\ \(0\)\
\-\ to\\:\\ 0\\.004918250769017116\ \(0\)\
\-\ 6\\:\\ 0\\.004898503188819336\ \(0\)\
\-\ primary\\:\\ 0\\.004858702999799801\ \(0\)\
\-\ pulmonary\\:\\ 0\\.004791843205796667\ \(0\)\
\-\ when\\:\\ 0\\.004697372816921316\ \(0\)\
\-\ weeks\\:\\ 0\\.004655043679272837\ \(0\)\
\-\ time\\:\\ 0\\.004632631914086972\ \(0\)\
\-\ performed\\:\\ 0\\.004573087008113856\ \(0\)\
\-\ y\\/o\\:\\ 0\\.004542474145527141\ \(0\)\
\-\ are\\:\\ 0\\.004471684731399622\ \(0\)\
\-\ at\\:\\ 0\\.004444388302616634\ \(0\)\
\-\ therapy\\:\\ 0\\.004385107094511733\ \(0\)\
\-\ \\:\\:\\ 0\\.00433886685601023\ \(0\)\
\-\ than\\:\\ 0\\.0042975985699007175\ \(0\)\
\-\ patients\\:\\ 0\\.004244864874023082\ \(0\)\
\-\ prior\\:\\ 0\\.004211348890983423\ \(0\)\
\-\ for\\:\\ 0\\.004198319473950375\ \(0\)\
\-\ both\\:\\ 0\\.004188483667343803\ \(0\)\
\-\ \\(\\:\\ 0\\.00415947251196081\ \(0\)\
\-\ \\)\\:\\ 0\\.004108662334625557\ \(0\)\
\-\ more\\:\\ 0\\.004102065852806461\ \(0\)\
\-\ symptoms\\:\\ 0\\.004087634312664374\ \(0\)\
\-\ bilateral\\:\\ 0\\.003980456294269566\ \(0\)\
\-\ chest\\:\\ 0\\.003924623800494277\ \(0\)\
\-\ 1\\:\\ 0\\.0039027377504025082\ \(0\)\
\-\ \\;\\:\\ 0\\.0038875646611374157\ \(0\)\
\-\ a\\:\\ 0\\.0038061401326161346\ \(0\)\
\-\ of\\:\\ 0\\.003801467588418048\ \(0\)\
\-\ most\\:\\ 0\\.0037866317499579195\ \(0\)\
\-\ other\\:\\ 0\\.003780496254707195\ \(0\)\
\-\ were\\:\\ 0\\.003724158035873169\ \(0\)\
\-\ lower\\:\\ 0\\.003688794758855782\ \(0\)\
\-\ findings\\:\\ 0\\.0034910497807868705\ \(0\)\
\-\ right\\:\\ 0\\.003461158192362444\ \(0\)\
\-\ multiple\\:\\ 0\\.0034545220796147196\ \(0\)\
\-\ female\\:\\ 0\\.003371900712951696\ \(0\)\
\-\ within\\:\\ 0\\.003128851071758314\ \(0\)\
\-\ which\\:\\ 0\\.003061697864189153\ \(0\)\
\-\ normal\\:\\ 0\\.0025712331182324395\ \(0\)\
\-\ be\\:\\ 0\\.0025292835380881554\ \(0\)\
\-\ history\\:\\ 0\\.002265287020551024\ \(0\)\
\-\ and\\:\\ 0\\.0020730403731157596\ \(0\)\
\-\ with\\:\\ 0\\.0020211853835105714\ \(0\)\
\-\ pain\\:\\ 0\\.002003086693916957\ \(0\)\
\-\ was\\:\\ 0\\.0018968858391817404\ \(0\)\
\-\ left\\:\\ 0\\.001835134873844366\ \(0\)\
\-\ patient\\:\\ 0\\.0016441303856360612\ \(0\)\
\-\ \\.\\:\\ 0\\.001362746107383734\ \(0\)\
